Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 12/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | TTK | P33981 | 1/20 | 0.37 |
| ▸ | GRM6 | O15303 | 1/20 | 0.33 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.33 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.33 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.33 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | APEX1 | P27695 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20555195 | 0.84 | POLB (0.33) | POLBMAPTALDH1A1TDP1 | |
| SCHEMBL31081873 | 0.81 | GRM6 (0.31) | GRM6GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL20555201 | 0.78 | ALDH1A1 (0.33) | POLBMAPTALDH1A1TDP1 | |
| SCHEMBL24793186 | 0.77 | LRRK2 (0.32) | LRRK2 | |
| SCHEMBL20555353 | 0.76 | GPR35 (0.38) | POLBMAPTALDH1A1 | |
| SCHEMBL4559487 | 0.76 | MAPT (0.39) | POLBMAPTALDH1A1TDP1 | |
| SCHEMBL24752307 | 0.76 | LRRK2 (0.35) | LRRK2 | |
| SCHEMBL4561198 | 0.75 | GPR35 (0.37) | POLBMAPTALDH1A1 | |
| SCHEMBL15528397 | 0.75 | ALDH1A1 (0.35) | POLBMAPTALDH1A1 | |
| SCHEMBL20555297 | 0.75 | LRRK2 (0.36) | LRRK2POLBMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250313575-A1 | MACROCYCLES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2025-10-09 | — | — | US | disclosed |
| EP-4525875-A1 | MACROCYCLES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Merck Sharp & Dohme LLC (US) | 2025-03-26 | — | — | EP | disclosed |
| CN-117425660-A | Aromatic heterocyclic compound, intermediate thereof, pharmaceutical composition and application | 上海翊石医药科技有限公司 | 2024-01-19 | — | — | CN | disclosed |
| WO-2023222005-A1 | AROMATIC HETEROCYCLIC COMPOUND AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 上海翊石医药科技有限公司 | 2023-11-23 | — | — | WO | disclosed |
| WO-2023224894-A1 | MACROCYCLES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-11-23 | — | — | WO | disclosed |
| US-20220119371-A1 | COMPOUND, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2022-04-21 | — | — | US | disclosed |
| US-11214565-B2 | Compound, compositions, and methods | DENALI THERAPEUTICS INC. (US) | 2022-01-04 | — | — | US | disclosed |
| US-20180327391-A1 | COMPOUND, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. | 2018-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180327391-A1 | COMPOUND, COMPOSITIONS, AND METHODS | LRRK2, PARK7, MAPT | LRRK2 1/4885CYP1A2 3151/4885TTK 900/4885 |
| US-20220119371-A1 | COMPOUND, COMPOSITIONS, AND METHODS | LRRK2, PARK7, SNCA | LRRK2 1/4885CYP1A2 3146/4885TTK 929/4885 |
| US-11214565-B2 | Compound, compositions, and methods | LRRK2, PARK7, MAPT | LRRK2 1/4885CYP1A2 3151/4885TTK 900/4885 |
| US-20250313575-A1 | MACROCYCLES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | LRRK2, CLK2, PARK7 | LRRK2 1/4885CYP1A2 3233/4885TTK 312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.